Revenue from Pfizer's COVID-19 vaccine and treatment, which peaked at $57 billion in 2022, are now expected to be $8 billion in 2024, a further drop from the $13 billion analysts' forecast and Pfizer's own lowered view of $12.5 billion for this year.